Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
AEON.......................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783
AEON..............................................https://stockcharts.com/h-sc/ui?s=AEON&p=W&b=5&g=0&id=p86431144783
AEON repositions ABP-450 as_a potential Botox biosimilar:
https://finance.yahoo.com/news/aeon-biopharma-announces-strategic-reprioritization-120000126.html
AEON is nearly insolvent (#msg-174417740), so it’s hard to see how they complete a phase-3 trial to obtain FDA approval using the 351(k) pathway.
This looks like another instance of Zebra’s Law.
Reminder: ABP-450 is the same drug as EOLS’ Jeuveau, sourced from Korea’s Daewoong.
AEON—>55% workforce reduction—ABP-450 clinical development suspended:
https://finance.yahoo.com/news/aeon-biopharma-announces-strategic-reprioritization-120000294.html
AEON has a liquidity problem—1Q24 results:
https://www.globenewswire.com/news-release/2024/05/14/2881873/0/en/AEON-Biopharma-Reports-First-Quarter-2024-Financial-Results.html
Net current assets at 3/31/24 were negative ($13.5M). Hence, even after accounting for the $15.0M AEON received from its supplier, Daewoong in an Apr 2024 private placement, net current assets as of today are either close to zero or negative.
No CC.
AEON—(-53%)—reports failed phase-2 in migraine prevention:
https://finance.yahoo.com/news/aeon-biopharma-announces-preliminary-top-110000987.html
Dilution from the redemption of warrants:
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001837607/000183760724000017/aeon-20240329x8k.htm
AEON sells $15M of convertible debt to_supplier, Daewoong:
https://finance.yahoo.com/news/aeon-biopharma-announces-15-million-202900910.html
AEON presents phase-2 data in cervical dystonia:
https://finance.yahoo.com/news/aeon-biopharma-presents-positive-clinical-210500488.html
CD had been AEON’s lead indication for ABP-450, but AEON changed gears and made episodic migraine the lead indication after RVNC reported Daxxify data in CD (https://www.sec.gov/Archives/edgar/data/1837607/000110465923063774/tm2316532d1_ex99-1.htm ). When AEON’s phase-2 in episodic migraine failed in Oct 2023 (#msg-173058579), CD again became the lead indication by default.
The above PR also includes preclinical data for ABP-450 in PTSD (!?).
AEON needs to raise a significant amount of cash to conduct a phase-3 trial in any indication (#msg-173211412).
Reminder: ABP-450, sourced from Korea’s Daewoong, is the exact same toxin as EOLS’ Jeuveau. See #msg-172274907 for background info.
AEON phase-2 trial_in episodic migraine misses_ primary_endpoint:
https://finance.yahoo.com/news/aeon-biopharma-announces-topline-results-200500504.html
AEON's trading liquidity is so low it doesn't take much to move the share price. Today's news was actually minor in the overall scheme of things insofar as AEON has apparently put the brakes on its clinical program in cervical dystonia in order to pursue episodic migraine.
AEON presents phase-2 data in cervical dystonia:
https://finance.yahoo.com/news/aeon-biopharma-presents-positive-results-120000687.html
Note: Episodic migraine, rather than cervical dystonia, is now AEON’s lead indication for ABP-450. This change is presumably due to RVNC’s robust data in cervical dystonia and the recent FDA approval of Daxxify for CD.
See #msg-172274963 for related info.
AEON's initial press release:
https://finance.yahoo.com/news/aeon-biopharma-announces-closing-business-110000037.html
$AEON This is the one Im watching/trading tomorrow....GLTY......
AEON’s corporate slide presentation:
https://www.sec.gov/Archives/edgar/data/1837607/000110465923063774/tm2316532d1_ex99-1.htm
Notably, AEON’s lead indication is now episodic migraine. AEON’s lead indication was previously cervical dystonia, so it seems reasonable to surmise that RVNC’s stellar data in CD altered AEON’s plans.
AEON seeks_to_compete_in_the therapeutic—(rather than aesthetic)—market_for botulinum toxin. AEON's botulinum toxin, ABP-450 is the exact same product as EOLS’ Jeuveau, sourced from Korea's Daewoong.
AEON Biopharma begins_trading_7/24/23_under_the_symbol, AEON, following the closing of the SPAC merger with PMGM:
https://finance.yahoo.com/news/priveterra-acquisition-corp-announces-completion-202700149.html
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
30
|
Created
|
07/21/23
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |